The task of recruiting patients for a research project can prove to be the most difficult aspect of the entire research process. A large portion of the work of research is devoted to the identification of strategies which ensure a successful recruitment of patients. Every researcher has learned from experience the many methods needed to enhance patient enrollment into trials. Superiority trials in SLE have not been frequent in previous years. This paper describes the challenges encountered with the multicentre SMILE trial in progress across Canada. We identify areas where patient recruitment is a problem, potential reasons for the problem, and the results of tactics used to increase enrollment.
Tan E , Cohen A , Fries J et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271-1277 .
2.
Hochberg C.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] . Arthritis Rheum1997; 40: 1725-1725 .
3.
Dubois E (ed.) Lupus Erythematosus. A review of the current status of discoid and systemic lupus erythematosus and their variants, 2nd ed revised. Los Angeles: USC Press , 1976.
4.
Miescher P , Riethmuller D . Diagnosis and treatment of systemic lupus erythematosus . Sem Hematol1965; 2: 1-28 .
5.
Davidson J , Graziano F , Grandone J et al. The use of methotrexate in steroid-resistant systemic lupus erythematosus . Arthritis Rheum1988; 31: 612-615 .
6.
Wilke W , Krall P , Scheetz R et al. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases . Clin Exp Rheumatol1991; 9: 581-587 .
7.
Wilson K , Katz J , Abeles M . The use of methotrexate in systemic lupus erythematosus . Arthritis Rheum1991; 34: R39-R39 .
8.
Wallace D.Cytotoxic drugs. In: Wallace D , Hahn B (eds.) Dubois' Lupus Erythematosus. Philadelphia: Lea and Febinger , 1999, p 595-595.
9.
Abud-Mendoza C , Sturbaum A , Vasquez-Compean R , Gonzalez-Amaro R . Methotrexate therapy in childhood systemic lupus erythematosus . J Rheum1993; 20: 731-733 .
10.
Morelli S , Giodano M , De Marzio P et al Pulmonary arterial hypertension responsiveness to immunosuppressive therapy in systemic lupus erythematosus . Lupus1993; 2: 367-369 .
11.
Fox D , McCune W . Immunosuppressive drug therapy of systemic lupus erythematosus . Rheum Dis Clin North Am1994; 21: 265-299 .
12.
Walz-LeBlanc BAE , Dagenais P , Urowitz M , Gladman D . Methotrexate in systemic lupus erythematosus . J Rheumatol1994; 21: 836-868 .
13.
Kipin Y , Littlejohn G , Morand E . Methotrexate use in systemic lupus erythematosus . Lupus1997; 6: 385-389 .
14.
Gansauge S , Breitbart A , Rinaldi N , Schwarz-Eywill M . Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease) . Ann Rheum Dis1997; 56: 382-385 .
15.
Wise C , Vuyyuru S , Roberts W . Methotrexate in nonrenal lupus and undifferentiated connective tissue disease a review of 36 patients . J Rheumatol1996; 23: 1005-1010 .
16.
Fink S , Kremer J . Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexate . J Rheumatol1995; 22: 967-969 .
17.
Gibinski K.Selection and recruitment of patients for biomedical experiments. In: Howard-Jones N , Bankowski Z (eds.) Medical Experimentation and the Protection of Human Rights. Geneva: Council for International Organizations of Medical Sciences; Sandoz Institute for Health and Socio-Economic Studies , 1979, pp 142-153.
18.
Rosenstock I.Historical origins of the health belief model . Health Edu Monogr1974; 2: 328-335 .
19.
Rimer B.Participant enrollment, participation and compliance in chemoprevention trials. In: Newell G , Hong W (eds.) The Biology and Prevention of Aerodigestive Tract Cancers. New York. Plenum Press , 1992, pp 111-117.
20.
Edworthy S , Domazet N , Talavera R , Devins G . Illness instrusiveness: an intervening factor between symptoms and quality of life in patients with systemic lupus erythematosus . Arthritis Rheum1998; 41: S262-S262 .
21.
DaCosta D , Dobkin P , Fortin P et al. Illness intrusiveness mediates the relationship between disease activity and psychological distress in women with SLE [abstract] . 30th Laurentian Conference of RheumatologyMay 28 and 29, 1999.
22.
Spilker B . Patient recruitment. In: Spilker B (ed.) Guide to Clinical Trials. New York: Raven Press , 1992; pp 85-92.
23.
Sullivan K , Hébert P , Logan J et al. What do physicians tell patients with end-stage COPD about intubation and mechanical ventilation . Chest1996; 109: 258-264 .
24.
Pawlik-Plank D.Framing treatment options: a method to enhance informed consent . Clin Nurse Special1994; 8: 174-178 .
25.
O'Connor A.Effects of framing and level of probability on patients' preferences for cancer chemotherapy . J Clin Epidemiol1989; 42: 119-126 .
26.
Teasdale K.Information and anxiety: a critical reappraisal . J Adv Nurs1993; 18: 1125-1132 .
27.
O'Connor A , Pennie R , Dales R . Framing effects on expectations, decisions, and side effects experienced: the case of influenza immunization . J Clin Epidemiol1996; 49: 1271-1276 .
28.
Shea S , Bigger JJ , Campion J et al. Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrythmia suppression trial (CAST) . Control Clin Trials1992; 13: 466-486 .
29.
DeLuca S , Lorcuska L , Oberstar B et al Are we promoting true informed consent in cardiovascular clinical trials?J Cardiovasc Nurs1995; 9: 54-61 .
30.
Polit D , Hungler B . Ethics and scientific research. In: Polit D , Hungler B (eds.) Nursing Research: Principles and Methods. Philadelphia: JB Lippincott Co , 1991, pp 29-47.
